G1 Therapeutics Faces Setback in Phase 3 Trial
Shares of G1 Therapeutics took a major hit, falling 46% to $2.44 in after-hours trading on Monday, following an update on its Phase 3 trilaciclib combination trial. Trial Continuation Recommended…
Reviva Pharmaceuticals Announces Positive Results in Phase 3 Trial for Brilaroxazine
Reviva Pharmaceuticals Holdings announced today the successful completion of its pivotal Phase 3 trial evaluating the efficacy, safety, and tolerability of brilaroxazine in treating schizophrenia in adults. The trial yielded…
Phase 3 Trial for Melanoma Treatment
Merck & Co. (MRK) and Moderna Inc. (MRNA) have announced the initiation of a Phase 3 trial to evaluate the efficacy of Moderna's V940 in combination with Merck's Keytruda as…
Panbela Therapeutics Receives Positive Recommendation for Phase 3
Panbela Therapeutics saw a significant boost in its shares, which increased by 11% and reached $2.38. This surge came after the independent Data Safety Monitoring Board recommended advancing the Phase…